StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for GENB yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $15.25 | $16.00 | +4.92% | 1.4M |
| 05-18 | $15.25 | $13.01 | -14.72% | 1.8M |
| 05-19 | $13.10 | $12.42 | -5.19% | 0.7M |
| 05-20 | $12.63 | $13.02 | +3.09% | 0.9M |
| 05-21 | $13.62 | $13.98 | +2.64% | 1.0M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q1 2025 2025-03-31 |
|---|---|---|
Revenue | $7.22M | $8.82M |
Operating Income | $-64.11M | $-48.15M |
Net Income | $-61.45M | $-41.69M |
EPS (Diluted) | $-1.07 | $-1.62 |
Total Assets | $625.74M | Not available |
Total Liabilities | $110.94M | Not available |
Cash & Equivalents | $160.57M | $220.61M |
Free Cash Flow OCF − CapEx | $-84.17M | $-53.93M |
Shares Outstanding | 128.19M | 32.79M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.